Lots of interesting abstracts and cases were submitted for TCTAP & AP VALVES 2020 Virtual. Below are accepted ones after thoroughly reviewed by our official reviewers. Don¡¯t miss the opportunity to explore your knowledge and interact with authors as well as virtual participants by sharing your opinion!
* The E-Science Station is well-optimized for PC.
We highly recommend you use a desktop computer or laptop to browse E-posters.
ABS20190926_0003
| Renal Insufficiency and Contrast Nephropathy | |
| Correlation Between Iso-Osmolar / Low-Osmolar Contrast Exposure and Contrast Induced Nephropathy and 2-Year Outcomes After Coronary Artery Intervention | |
| Mengyang Du1, Jinqing Yuan1 | |
| Fuwai Hospital, China1 | |
|
Background:
This study investigated the correlation between iso-osmolar/low-osmolar contrast agents and contrast-induced nephropathy (CIN) and long-term prognosis after interventional therapy for coronary heart disease.
|
|
|
Methods:
All patients who underwent interventional therapy in Fuwai Hospital in 2013 were enrolled. A total of 9903 patients were enrolled in the cohort according to the exclusion criteria. According to the type of contrast agent used, the iso-osmolar contrast group and the low-osmolar contrast group were analyzed. Correlation between Iso-osmolar contrast exposure and contrast induced nephropathy and 2-year outcomes after coronary artery intervention were analyzed.
|
|
|
Results:
The incidence of contrast induced nephropathy was 6.2% and 9.0% in the iso-osmolar contrast group (n=1691) and the low-osmolar contrast group (n=8212), respectively, p < 0.001. The multivariate analysis showed that the use of iso-osmolar contrast agents significantly reduced the incidence of contrast induced nephropathy compared with low-osmolar contrast agents, p < 0.001. COX regression analysis showed that the use of iso-osmolar contrast agents did not affect the incidence of 2 years all-cause mortality (p > 0.05)
|
|
|
Conclusion:
Compared with low-osmolar contrast agents, iso-osmolar contrast significantly reduced the incidence of contrast induced nephropathy after percutaneous coronary intervention, but had no significant effect on 2-year all-cause mortality.
|
|
0